














Do not disseminate or use without explicit permission from 
the authors 
 
Safety of nalmefene for the treatment of alcohol use disorder: an update 
Abstract 
Introduction  
Reduced drinking has been debated as a treatment goal for heavy drinking alcohol dependent 
patients, in whom treatment based on abstinence is not always an option. Nalmefene was the 
first drug approved by the European Medicines Agency (2013) with the indication of reduced 
drinking in high drinking risk level alcohol dependent patients. Six years after its introduction in 
Europe, data from clinical experience can be compared with those from preclinical studies and 
pivotal registration studies to evaluate what nalmefene has added to the treatment of AUD. 
Areas covered: Systematic review of efficacy and safety data of nalmefene use in humans from 
preclinical, phase III and phase IV studies, including systematic reviews, meta-analyses, cost-
effectiveness analyses and other secondary analyses. 
Expert opinion: Nalmefene introduces a paradigm change in the treatment of AUD that make 
it appealing to patients that are reluctant to embrace abstinence, and facilitate patient-
centered care in heavy users. However, information regarding safety data in special 
populations (e.g., patients with alcohol-related diseases, pregnancy, psychiatric disease), and 
direct comparisons with other potential drugs for alcohol reduction are further needed. 
Despite the promising role of nalmefene, there are still some factors that limit its wide 
prescription further than in specialized settings.  
Keywords: alcohol use disorders, nalmefene, safety, harm-reduction, adverse effects 
Article highlights  
 Three quarters of nalmefene users experienced adverse events in phase III studies 
whereas 2/3 of the placebo group also reported AEs.  
 The most common adverse events were mild/moderate (nausea, dizziness, headache, 
insomnia) and in most cases did not lead to nalmefene withdrawal (phase III). 
 The frequency of AEs in phase IV studies is lower than in phase III RCTs. However, the 
report of AEs in these studies varies considerably (20-68%).  
 Efficacy results from phase III studies have been confirmed by phase IV studies.  
 Phase IV studies provide limited data regarding safety in patients affected by mental 
health problems. 
 Safety data in pregnancy, breastfeeding, severe hepatic impairment and renal 



















Alcohol related costs are very high in western societies, and exceed by far the revenues 
obtained from taxation [1]. In Europe, the costs of alcohol use are up to € 1,500 per capita per 
year [2], with most of the costs associated to binge drinking [3]. Alcohol is linked to more than 
200 health conditions [4], in a dose-response manner [5–7]. Alcohol use disorder (AUD) highly 
contributes to those costs and in fact has been identified as a potentially life-threatening 
disease. Treatment of AUD remains a challenge, an unmet medical need, for clinicians, 
researchers and policy makers [8]. Abstinence oriented programs are far from appealing to half 
of the people with an AUD, and reduced/controlled drinking is well accepted as a treatment 
goal in primary health settings, but scarcely used with heavy drinkers in specialized care. 
Several medications (e.g., naltrexone) have shown mixed or negative results in terms of 
abstinence, but are promising in achieving reductions in drinking [9,10]. The potential role of 
nalmefene for reducing health consequences of alcohol use through reduced drinking is 
encouraging since evidence shows that reductions on heavy alcohol use are associated with 
decreased morbidity [5–7,11] and mortality [7,12]. Nalmefene is the only medication that has 
been specifically studied aiming at a reduction goal[13–15]. In addition, modeling studies have 
shown that nalmefene can be a cost-effective treatment preventing up to 7.179 alcohol-
attributable diseases and injuries and 309 deaths per 100 000 patients compared to 
psychosocial support alone in a period of 5 years [16–18]. Reduction in 9-year mortality risk 
due to nalmefene was estimated to be up to 8% [12]. According to phase III studies, safety and 
tolerability of nalmefene are good [17]. Since its market-launch, several phase IV studies and 
meta-analyses have been conducted, which allow an update on safety and tolerability based 
on real-world samples. Data regarding nalmefene effectiveness will also be revised.  
1.1. Background to the development and use of nalmefene  
In a clinical laboratory setting, nalmefene (40 mg) and naltrexone (50 mg) were tested in social 
drinkers (n=90) and alcohol dependent patients who were not seeking reduction (n=125) for 
eight days without a comparison group. Both drugs led to reductions in alcohol use and craving 
[19,20].  
The efficacy of nalmefene use in reducing alcohol consumption was studied in three 24-weeks 
randomized controlled trials (RCT) (ESENSE I [13] and ESENSE II [14] in Europe, and one study 
in Japan [21]) and a 52-week RCT (SENSE) [15]. In these trials, selection criteria were ≥ 18 years 
old (20 years old in Japan) with a diagnosis of alcohol dependence (DSM-IV-TR), at least 6 
heavy drinking days (HDD) (≥ 60 g for men and ≥ 40 g for women), an average alcohol 
consumption of at least medium drinking risk level (DRL) according to WHO classification [22], 
and less than 14 consecutive abstinent days in the four weeks preceding the screening.  
In ESENSE I, the effect of as needed nalmefene 20 mg (n=306) was statistically significant 
compared to placebo (n=298) in both primary outcomes (number of heavy drinking days-
HDDs- and Total Alcohol Consumption -TAC-) and secondary outcomes (γ-glutamyltransferase: 
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Impression- Severity of Illness Scale: CGI-S and Global Improvement Scale: CGI-I).  ESENSE II 
also found nalmefene 20 mg (n=358) to be significantly superior to placebo (n=360) in HDD but 
not in TAC. Secondary outcomes (ALAT, CGI-S) also improved in favor of nalmefene except for 
the CGI-I and GGT.  The Japanese RCT showed the efficacy of nalmefene 20 mg (n=248) and 
nalmefene 10 mg (n=184) versus placebo (n=245) in terms of HDD, TAC, and secondary 
outcomes (downward shift in DRL of two categories or more, proportion of patients with low 
or lower DRL, 70% decrease in TAC, proportion of patients with ≤4 HDD). 
A subgroup analyses of ESENSE I plus ESENSE II [23], of patients who had not reduced their 
alcohol consumption after the first contact with the researchers (n=667) showed at month six 
improvements in both primary outcomes, HDD (-3.2 95% CI -4.8 to -1.6; p<0.00001) and TAC (-
14.3 g/day 95% CI -20.8 to -7.8; p=0.00001) as well as in secondary outcomes (GGT and ALAT). 
A post hoc analyses of ESENSE I plus II aiming to analyze the impact on quality of life [24] 
(n=667) found that nalmefene was superior to placebo in improving SF-36 mental component 
(mean difference [MD] 3.09 95% CI 1.29 to 4.89; p=0.0008), physical component (MD 1.23 95% 
CI 0.15 to 2.31; p=0.026), EQ-5D index scores (MD 0.03 95% CI 0.00 to 0.06; p=0.045), EQ-5D 
health state scores (MD 3.46 95% CI 0.75 to 6.17; p=0.012), and DrInC-2R scores (MD -3.22 
95% CI -6.12 to 0.33; p=0.029). 
At month 12, in the SENSE study the reduction in the number of HDDs and TAC was statistically 
significant in favor of nalmefene (n=310) versus placebo (n=365), as well as for GGT and CGI-I, 
but there were no differences for Carbohydrate deficient transferrin (CDT) or CGI-S. 
In all previous studies [13–15,21] both groups received concomitant BRENDA psychosocial 
intervention [25].  Table 1 shows a summary of efficacy results. 
The efficacy of nalmefene in reducing alcohol consumption has also been reviewed in at least 
four meta-analyses [10,26–28] including both published [13–15,29–31] and unpublished (CPH-
101-0399, CPH-101-0701, CPH-101-0801) trials.  According to Mann et al (2016) [26], random 
effects were in favor of nalmefene 20 mg for the number of HDDs (Hedges’ g -0.20 95% CI -
0.30 to -0.09) and for TAC (Hedges’ g -0.33 95% CI -0.48 to -0.18). Higher doses (40mg) did not 
increase the favorable effects. For the patients with High DRL according to WHO criteria who 
were not early reducers, the random effects were higher: HDD was -0.33 (95%CI -0.48 to -0.18) 
and for TAC was -0.35 (95% CI -0.51 to -0.20).  
Similarly, a meta-analysis of five RCTs found differences in favor of nalmefene for HDD at 
month 6 (MD −1.65, 95% CI −2.41 to −0.8) and at month 12 (MD −1.60, 95% CI −2.85; −0.35), 
and also for TAC at month 12 (MD −0.20, 95%CI−0.30 to −0.10). No benefit was found 
regarding mortality or quality of life [28].   
The comparative effectiveness of drugs used to achieve controlled drinking was explored in 
two meta-analyses. A network meta-analysis [10] found that nalmefene, baclofen and 
topiramate were superior to placebo, and that topiramate was superior to other medications 
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0.29 to -0.10) and for HDD (MD -0.22 95% CI -0.32 to -0.12). This meta-analysis did not include 
studies with enough power for exploring health outcomes.   
Finally, an indirect meta-analysis [27] of 17 RCTs, including 4 RCTs of nalmefene and 13 RCTs of 
naltrexone did not find statistical significance differences between the two active medications. 
2. Body of review 
2.1. Mechanism of action 
As a µ and δ-opioid antagonist, nalmefene reduces the pleasant and positive reinforcing 
properties of alcohol[32,33], and as a κ-opioid partial agonist it probably enhances its sedative 
and dysphoric properties and also reduces craving for alcohol and impulsivity that promotes 
alcohol drinking [32].  
Nalmefene further differs from naltrexone by its longer plasma half-life, higher bioavailability 
and lower liver toxicity [29,32], and more effective binding to central opioid receptors as 
naltrexone blocks on δ-opioid receptors to a smaller extent than nalmefene [34]. It is rapidly 
absorbed after oral administration, peak plasma level is reached within 90 min after ingestion 
and half-life is 13.4 h after a single dose. Nalmefene occupies more than 80% of the MOR 
receptors up to 72 hours [35,36]. Nalmefene is extensively metabolized in the liver, largely by 
glucuronidation rather than turn into a different metabolite. 
Unlike naltrexone, nalmefene is also a partial agonist for ĸ-opioid receptor (KOR) in humans 
[37]. Chronic alcohol exposition enhances the KOR system activity in the nucleus accumbens 
that leads to a negative emotional state when alcohol consumption is decreased or stopped, 
which is followed by craving and negative reinforcement when alcohol again becomes 
available. Preclinical data indicate that the modulation of KOR system decreases dependence-
induced alcohol self-administration [38].  
As with naltrexone, there are no clinical safety concerns around its co-ingestion with 
alcohol[39], and in vitro studies have indicated that it has not relevant interactions with other 
drugs metabolized by the CYP450 and uridine 50-diphospho-glucuronosyltransferase (UDP)-
glucuronosyltransferase (UGT) systems. Chronic use of potent inhibitors of the UGT2B7 system 
(e.g. diclofenac) may increase nalmefene levels, but occasional use does not [40]. 
2.2. Clinical applications 
Phase IV studies  
Four studies have been conducted in specialized treatment units (n=110) [41,42], primary care 
settings(n=330) [43] and in psychiatric outpatients (n=65, n=25) [44,45]. They were single-
arm/naturalistic [41,42,44] or open-label studies [43] with follow-ups ranging from eight weeks 
to six months. In these studies it was found that nalmefene decreased HDD and TAC, and 
improved secondary outcomes, including reduction in daily alcohol consumption of at least 
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Symptom List-23 and the Clinical Global Impression Scale for Borderline Personality Disorder. 
For more details see table 1.  
2.3. Safety evaluation 
2.3.1. Safety in pre-marketing studies 
Within the safety and tolerability analysis of randomized phase III studies of nalmefene versus 
placebo -ESENSE1 [13], ESENSE2 [14] and SENSE [23]-, up to 75% of patients in the nalmefene 
group and 63% in the placebo group reported adverse events (AEs). These differences were 
statistically significant in the ESENSE1 and SENSE studies. Nausea, dizziness, headache, and 
insomnia were the most frequent symptoms in the nalmefene group, with 13% of the patients 
abandoning the medication, compared to 6% in the placebo group. Most AEs were transient, 
with an average length of 3 to 7 days and occurred during the first days of medication use. 
Psychiatric AEs were reported in 2.9% of the patients, mainly confusional symptoms, generally 
occurring after the first dose and with a short duration [17]. 
The frequency of AEs in the Japanese study was 86.6% in the nalmefene group compared to 
79.2% in the placebo group [21]. AEs were similar to those in the previously mentioned trials, 
being most mild or moderate in severity, and leading to discontinuation in about 2% of 
patients for either the 20 mg or 10 mg nalmefene. The 10 mg dose was associated with about 
5% lower rates of dizziness, malaise, somnolence and vomiting compared to the 20 mg dose. 
The rates of other AEs were generally similar between the two doses.  
In the Japanese study, serious AE (SAE) were reported in all treatment groups, occurring in two 
patients (0.8%) in the nalmefene 20 mg group, two patients (1.1%) in nalmefene 10 mg group, 
and two patients (0.8%) in the placebo group. SAEs in the nalmefene group were chronic 
hepatitis and gastroenteritis at a dose of 20 mg, femur fracture and spinal compression 
fracture (both occurred in the same patient), and one death at a dose of 10 mg. The cause of 
death was unknown and its association with the treatment could not be ruled out. 
2.3.2. Post-marketing data 
In the study conducted by Barrio et al, with 110 patients, 29 patients (26.4%) presented 
medication-related adverse events during the first month of treatment. The most frequent AEs 
were dizziness, nausea, somnolence, and cognitive numbness. No SAEs were recorded [41]. At 
six months, no new drug-related AEs were notified [42]. 
Results from the multicenter open-label study by Castera et al (2019) [43], point out that 
nalmefene was well tolerated. From the 330 patients included, 19 (6.4%) withdrew from the 
study due to adverse events (mainly nausea and dizziness). Overall, 68% of patients in the 
nalmefene cohort had one or more AEs, most of which were mild or moderate in severity. A 
total of 22 patients (7%) reported SAEs, describing alcohol withdrawal syndrome, depressive 
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In the Di Nicola et al study [44] with 65 patients, 24 patients (38.5%) showed AEs, being 
dizziness, nausea, headache and insomnia the most common. These AEs mostly occurred after 
the first dose, had a short duration and were mild or moderate in intensity. Similarly, Martin-
Blanco et al[45], found that the most common adverse events were dizziness, nausea, 
decreased appetite, and unsteady gait (n=5, 20%). Two patients withdraw the medication due 
to nausea, dizziness, and unsteady gait (n=1) and nausea and malaise (n=1) [45]. 
A meta-analyses of eight RCTs found no increased risk of SAEs in patients with substance use 
or impulse control disorder (n=1,828) treated with nalmefene compared to placebo (n=1,119) 
[46]. However, patients taking nalmefene were 3.22 times more likely to withdraw due to 
adverse events. In the withdrawal stratified analysis, no statistical differences among patients 
with substance use or impulse control disorder were observed. The risk of withdrawal due to 
adverse events of nalmefene was also supported by the meta-analysis of Jonas et al. (2014) 
[47].  
Table 2 shows a summary of adverse events from phase III and IV studies.   
2.3.3. Safety in special populations (Table 3). 
2.3.3.1. Opiate-dependent patients.  
Nalmefene, being a modulator of the opioid system, interacts with other opioids (methadone, 
buprenorphine, codeine) and may precipitate an opiate withdrawal syndrome. It has been 
reported in patients with opioid abuse (oxycodone or codeine) and in maintenance therapy 
with methadone and buprenorphine [48]. The development of withdrawal syndrome can occur 
in a variable range of severity, requiring medical observation in most of the cases and even 
treatment in intensive care, as reported in two cases [49]. For this reason it is recommended 
to document the use of other substances and to be cautious in those patients with opioid 
abuse or under opioid treatment for pain or opioid dependence [50].  
2.3.3.2. Psychiatric disorder 
Nalmefene has been studied in patients with stable psychiatric diseases [15,42] showing that 
patients with AUD and psychiatric comorbidity (n=42) experienced adverse events after 6 
months of nalmefene use with the same frequency as the general population (40%) [44]. Also, 
in a small open non-controlled trial carried out in 25 individuals with Borderline Personality 
Disorder and AUD, nalmefene showed a good tolerability and only five out of 25 participants 
(20%) reported mild AEs, that led to the cessation of the treatment in only two of the cases 
(8%) [45]. The development of psychotic symptoms 48 hours after starting nalmefene 
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with a history of depressive disorder [52] presented  somnolence, asthenia and fatigue 48 
hours after nalmefene use [52]. These symptoms remitted after drug discontinuation. One 
case of severe central sleep apnea after 4 months of treatment with nalmefene was reported 
in a woman with depressive disorder and obesity [53]. 
2.3.3.3. Renal impairment 
Pharmacokinetic studies pointed out that the volume of distribution of nalmefene was 
significantly higher and the total body clearance lower in patients with End-Stage Renal 
Disease compared to patients with normal renal function [54]. No significant impairment of 
kidney function was reported during the use of nalmefene in alcohol dependent patients [46]. 
Although the use of opioid system modulators is not recommended in patients with severe 
renal failure, a direct toxicity on kidney function can be excluded and dose adjustment is not 
required in mild to moderate renal failure [55].  
2.3.3.4. Hepatic impairment 
The clearance of nalmefene was found to be significantly reduced in a small study of 12 
patients with liver disease compared to control subjects. The reduction in the clearance was 
inversely proportional to the severity of liver disease and also the changes in glucuronidation 
may only occur with more advanced disease [56]. Although there is no evidence of 
hepatotoxicity associated with nalmefene [57], there is a lack of data involving patients with 
advanced liver disease. Furthermore, abstinence is the preferred treatment goal for this group 
of patients, which is not the intended treatment goal of nalmefene [58]. 
2.3.3.5. Pregnancy and breastfeeding 
Data on the effects of nalmefene in these two conditions are lacking. 
2.3.3.6. Pharmacogenomics data 
The only pharmacogenomics analysis of a randomized placebo-controlled multicenter study 
[31] found no evidence that allelic variation in opioid receptor genes moderated the response 
to nalmefene treatment [59].  
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A cohort study with medical administrative data from the French national health insurance 
information system database (SNIIRAM) included patients aged 18 to 70 years, with no serious 
comorbidities initiating baclofen or approved medications for the treatment of alcohol 
dependence (nalmefene, naltrexone, acamprosate) between 2009 and 2015 [60]. Primary and 
secondary outcomes at one year follow-up were death from any cause and death due to 
specific causes, respectively. The study included 165.334 patients, 28.8% exposed to baclofen 
and 71.2% exposed to the other approved medications. After multivariate analysis, the risk of 
hospitalization and death was higher for patients treated with baclofen versus approved 
medications (HRf = 1.13 [1.09‐1.17] and HRf = 1.31 [1.08‐1.60], respectively). Despite the 
increase in hospitalization and mortality in patients treated with baclofen, in a recent 
systematic review and meta-analysis with 6036 patients and 32 RCT, no differences were 
found for any treatment (nalmefene, naltrexone, topiramate, baclofen, acamprosate) on 
mortality and serious adverse events. However, more adverse events and withdrawals for 
safety reasons were evidenced for naltrexone and nalmefene, and withdrawals increased for 
nalmefene [10]. 
In a meta-analysis of the benefits and harms of medications (US FDA-approved and others) for 
adults with AUD, patients treated with naltrexone or nalmefene had a higher risk of 
withdrawal due to adverse events with a Number Need to Harm (NNH) for naltrexone of 48 
(95% CI, 30 to 112; 17 trials, n=2743); and NNH for nalmefene of 12 (95% CI, 7 to 50; 5 trials, 
n=2054), compared with placebo. In the analysis for acamprosate or topiramate no significant 
differences compared to placebo were found. Those treated with nalmefene had a higher risk 
of dizziness, headache, insomnia nausea and vomiting [47].A randomized study to receive 
placebo, naltrexone (titrated to 50 mg/day), or nalmefene (titrated to 40 mg/day) among non 
treatment-seeking alcoholics and social drinkers, patients treated with nalmefene reported 
significantly higher levels of mild/moderate AEs as poor sleep, irritability, nausea/vomiting and 
impaired attention in comparison to placebo and naltrexone [19]. 
3. Conclusion 
Nalmefene has shown its efficacy in short-term (24-weeks) and long-term studies (52-weeks) 
in at least four studies under the reduction paradigm, especially in those patients with a higher 
drinking risk level. These results have been confirmed by meta-analyses and post-marketing 
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this topic are needed. Morbidity and mortality must be taken into account as main outcomes 
in observational studies and clinical trials.  
Most patients (70-90%) treated with nalmefene during the phase III studies had adverse 
events but these were mild to moderate allowing in most cases to continue the treatment. 
Although the frequency of adverse events in post-marketing studies is similar to those 
observed in clinical studies involving more patients with extensive follow-up are needed.  Also, 
only two-phase IV studies provide data on the frequency of withdrawal due to AEs.  
Differences in the frequency of AEs between the studies could be attributed both to the 
differences in their design, the greater number of patients and the closer monitoring of AEs in 
RCTs. 
Safety of nalmefene is similar to other drugs according to observational studies and meta-
analyses. The increased reporting of CNS symptoms (dizziness, insomnia, 
confusion/disorientation) in patients treated with nalmefene in comparison to naltrexone, 
despite having a similar safety profile, may be due to nalmefene action as a partial agonist at 
the KOR system. However, it is not known whether this difference in kappa-opioid receptors 
activity between the two drugs is reflected in differences in their efficacy in reducing drinking 
or in side effects.  
Interpretation of the findings must be prudent due to the fact that most of the existing 
literature is sponsored by the industry. 
4. Expert opinion 
Although naltrexone is used in several countries with the goal of reducing alcohol consumption 
in patients with moderate or severe AUD[61], nalmefene was the first and only treatment 
approved in Europe specifically for reduced drinking in alcohol dependent patients. In 
comparison to other approaches, this reduction goal may enhance treatment participation of 
AUD patients who feel not able or are not willing to stop drinking completely. It is the first and 
only medication for alcohol dependence that is used “as-needed” which may enhance self-
efficacy and patient empowerment.  
Alcohol reduction goal was available for a long time in mild/moderate AUD patients. With 
some exceptions (e.g., The Sinclair Method [62]), abstinence used to be the unique goal 
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care in heavy users [42] according to patients’ preferences, values and ongoing context. The 
offer of treatments with a reduction goal may be appealing to large numbers of patients who 
are reluctant to embrace an abstinence oriented program.  
Nalmefene introduces a paradigm change in the treatment of AUD. On one hand it may be 
appealing to many physicians, since it avoids the ‘abstinence goal’ and decreases the risk of 
labeling and stigmatization. On the other hand, it implies a shift in routine clinical practice that 
may be difficult, especially in specialized settings. 
Besides that, the drug has faced relevant problems in most of the EU countries concerning the 
co-payment by the Health system, leading to lower prescription rates. 
Safety data in populations with alcohol-related diseases (e.g. hepatic or cognitive impairment), 
and in breastfeeding and pregnancy are still needed.  Further information is needed to know 
the cost-effectiveness of nalmefene, specifically regarding health outcomes and direct/indirect 
costs. Morbidity and mortality outcomes must be assessed specifically in populations where 
the reduction approach is controversial, such as alcoholic-liver disease or alcohol-related 
cognitive impairment.  
Direct comparisons with other potential drugs for alcohol reduction are also needed (both for 
safety and effectiveness reasons). Long-term efficacy has been studied just in one phase III 
study. There is no data of long-term efficacy beyond 12 months or in phase IV studies.  
In our opinion, and according to the results from the studies reviewed in the present work, in 5 
years’ time, nalmefene should be widely available for its prescription in different settings, 
especially in primary care and in the emergency room. However, given its evolution in recent 
years, it is quite likely that the drug will remain mostly available in specialized settings.   
The recently published Study from Japan has given new positive data to the potential use of 
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